1. Home
  2. CDZI vs LYEL Comparison

CDZI vs LYEL Comparison

Compare CDZI & LYEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

CDZI

CADIZ Inc.

HOLD

Current Price

$3.01

Market Cap

342.2M

Sector

Utilities

ML Signal

HOLD

Logo Lyell Immunopharma Inc.

LYEL

Lyell Immunopharma Inc.

HOLD

Current Price

$12.94

Market Cap

320.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CDZI
LYEL
Founded
1983
2018
Country
United States
United States
Employees
31
N/A
Industry
Water Supply
Biotechnology: Pharmaceutical Preparations
Sector
Utilities
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
342.2M
320.1M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
CDZI
LYEL
Price
$3.01
$12.94
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$30.60
AVG Volume (30 Days)
1.3M
152.9K
Earning Date
05-14-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$36,000.00
Revenue This Year
$12.97
N/A
Revenue Next Year
$102.40
$8,712.13
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.87
$9.28
52 Week High
$6.96
$45.00

Technical Indicators

Market Signals
Indicator
CDZI
LYEL
Relative Strength Index (RSI) 35.92 46.74
Support Level N/A $12.45
Resistance Level $5.08 $14.14
Average True Range (ATR) 0.24 0.83
MACD -0.03 0.04
Stochastic Oscillator 20.41 35.35

Price Performance

Historical Comparison
CDZI
LYEL

About CDZI CADIZ Inc.

Cadiz Inc is a water solutions provider, dedicated to delivering clean, reliable, and affordable water for people. It provides water solutions with a combination of land, water, pipeline, and water filtration assets located in Southern California between key water systems serving population centers in the Southwestern United States. The company operates in two reportable segments; Land and Water Resources segment, comprises all activities regarding its properties in the eastern Mojave Desert, pre-revenue development of the Mojave Groundwater Bank (supply, storage, and conveyance), and agricultural operations; and the Water Filtration Technology segment, generating maximum revenue engaged in providing water filtration solutions for impaired or contaminated groundwater sources.

About LYEL Lyell Immunopharma Inc.

Lyell Immunopharma Inc s a late-stage clinical cell therapy company advancing a pipeline of proprietary next-generation autologous chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The Company's product candidate, rondecabtagene autoleucel (ronde-cel, also known as LYL314), is an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development for large B-cell lymphoma (LBCL). The Company has recently acquired exclusive rights outside of mainland China, Hong Kong, Macau and Taiwan, to a novel guanylyl cyclase C (GCC)-targeted CAR T-cell product candidate in early clinical development for refractory metastatic colorectal cancer (mCRC) and other GCC-expressing cancers.

Share on Social Networks: